skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration



Abbott Laboratories launching a new portable point-of-care test that can detect COVID-19 within five minutes, the company announced on March 27.

The new test, ID NOW COVID19, will run on Abbott’s portable POC platform ID NOW and deliver positive results in as little as five minutes, the company says. Negative results are delivered in thirteen minutes.

The test has been issued an emergency use authorization (EUA) by the US Food and Drug Administration and is expected to be available in the US this week.

As the pandemic unfolds, there have been repeated calls to increase availability of rapid testing. POC tests such as Abbott’s ID NOW may play an important role in diagnosing infection, but the sensitivity and specificity of these rapidly developed tests are also being questioned.

It is the second COVID-19 test to receive an EUA. Last week Abbott launched the Abbott m2000 RealTime SARS-CoV-2 test. Between the two platforms, Abbott said it expects to produce about 5 million tests per month.  (Also see "Abbott Receives Emergency Use Authorization For COVID-19 Test" - Medtech Insight, 19 Mar, 2020.)

[Editor’s note:Medtech Insight is tracking the global diagnostic pipeline of COVID-19 tests. See ourCOVID-19 test trackerfor a full listing.]

Read also

  • Medtech Insight: global medical technology news & analysis

    International Harmonization: Not Just For Audits Anymore

    By Elizabeth Orr 18 Sep 2020

    The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its...

  • Medtech Insight: global medical technology news & analysis

    QUOTED. 18 September 2020. Ed Israelski.

    18 Sep 2020

    The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski...

  • In Vivo: strategic insights for life sciences decision-maker...

    The Rise of Digital Tools eBook

    Explore how digital technologies are being used to address the disruption of clinical trials for drugs and medical technology caused by COVID-19. Stay current with insights from industry leaders, information on guidance and regulation, and an examination of how the challenges of this global crisis and the industry’s response to it may soon usher in a new era in worldwide healthcare.

    Topics Coronavirus


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: